Head-to-head · free
Faeth Therapeutics, Inc. vs Genmab
FTH vs GMAB — return on capital, cash generation, margins and balance sheet side by side.
FTH
1 / 2
measures where FTH leads
GMAB
1 / 2
measures where GMAB leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | FTH · FY2025 | GMAB |
|---|---|---|
| Revenue | — | — |
| Net income | (21.1M) | — |
| Revenue growth (yearly, multi-year) | — | — |
| Free cash flow | (20.5M) | — |
| Free cash flow margin | — | — |
| Net cash / (debt) | — | — |
| ROIC | — | 10.1% |
| Return on equity | -74.0% | 17.5% |
| Gross margin | — | 93.6% |
| Operating margin | — | 33.6% |
| Net debt / EBITDA | 0.39x | 3.13x |
Figures are as reported by each company; latest fiscal year shown.
Where Faeth Therapeutics, Inc.'s cash went (FY2025)
- Capital spending
- $16000
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free